NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Tuesday that it has reached a settlement with Abaxis over litigation the firms had filed against each other a couple of yeasr ago.

Abaxis filed suit against Cepheid in June 2010 claiming that the Sunnyvale, Calif.-based firm was infringing certain of its patents and was in breach of a licensing deal between the firms. Abaxis claimed that Cepheid had ceased paying royalties on a license that it took to US Patent No. 5,413,732, which covers reagents used in Cepheid's Xpert MRSA test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.